Can tracking MADD's natural course unlock better care?
NCT ID NCT07734090
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This study follows people with Multiple Acyl-CoA Dehydrogenase Deficiency (MADD) over time to learn how the condition progresses and affects daily life. Researchers will collect health data and patient feedback to identify patterns and potential markers of the disease. The goal is to build a clearer picture of MADD that could guide future treatments and improve quality of life for those affected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify key biomarkers and patient-reported outcomes that help design future treatments and improve care for MADD.
- What could go wrong
- This is an observational study, not a treatment trial, so it offers no direct benefit to participants. It may also face challenges in recruiting enough participants due to the rarity of MADD.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE ACYL-COA DEHYDROGENASE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States